<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863772</url>
  </required_header>
  <id_info>
    <org_study_id>A4091026</org_study_id>
    <nct_id>NCT00863772</nct_id>
  </id_info>
  <brief_title>Tanezumab and Nerve Function In Arthritis Patients</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of Tanezumab On Peripheral Nerve Function In Patients With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tanezumab reduces pain of osteoarthritis without affecting how nerve impulses are transmitted
      in sensory nerves.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was terminated on 16 Nov 2010 following a US FDA clinical hold for tanezumab
      osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June
      2010 for potential safety issues.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the composite measure (5NC [nd] + HRdb [nd])</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraepidermal nerve fiber density</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC subscales</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Arthritis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanezumab levels in the plasma</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tanezumab antibodies in the serum</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>5 mg dose Intravenously every 8 weeks for duration of study</description>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>10 mg dose Intravenously every 8 weeks for duration of study</description>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, Intravenously, every 8 weeks for duration of study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI less or equal to 39 kg/m2

          -  Osteoarthritis (arthritis) of the knee or hip with pain score that qualifies

          -  Willing to comply with study visit schedule and study requirements, including, for
             women of child-bearing potential or male patients with female partners of
             child-bearing potential, the use of 2 forms of birth control, one of which is a
             barrier method.

          -  Patients must consent in writing to participate in the study.

        Exclusion Criteria:

          -  Untreated, uncontrolled diseases,

          -  Unwilling or unable to discontinue the use of prohibited medications, including other
             pain medications, during the screening period and during the study,

          -  Significant cardiac disease within the past 6 months

          -  Significant neurological disease (e.g. peripheral neuropathy, multiple sclerosis,
             stroke) or signs of neuropathy at screening

          -  Known bleeding disorder or anticoagulation therapy

          -  Planned surgery during the study period

          -  History of alcoholism or drug abuse in the past 2 years

          -  Unable to use acetaminophen

          -  Use of a biologic (including live vaccines, with the exception of Flumist) within the
             past 3 months

          -  Allergic reaction to a biologic or an antibody in the past

          -  Disqualifying laboratory values, including Hepatitis B or C, HIV or drug test

          -  Cancer in the past 5 years. Basal cell or squamous cell carcinoma are okay.

          -  Medical condition that may interfere with study endpoints or safety of the subject as
             determined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091026&amp;StudyName=Tanezumab%20and%20Nerve%20Function%20In%20Arthritis%20Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <disposition_first_submitted>January 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 29, 2012</disposition_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

